IMW 2021 | The new era of myeloma therapies

Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, and Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, discuss novel therapies for the treatment of multiple myeloma, highlighting key combinations. Dr Mateos talks on the efficacy of B-cell maturation antigen (BCMA)-targeting therapies including bispecific antibodies, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, in the relapsed/refractory setting and calls for the earlier introduction of these novel targeted therapies into the treatment algorithm. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.